 |
(R)-1-(2,2-difluorobenzo [d][1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide |
|---|---|
| Trade Name | |
| Orphan Indication | Cystic fibrosis |
| USA Market Approval | USA |
| USA Designation Date | 2014-04-24 00:00:00 |
| Sponsor | Vertex Pharmaceuticals Inc.;50 Northern Avenue;Boston, Massachusetts, 02210 |
Related Access Program